APGE PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

APGE ▲ +1.23% at T+5d

NEUTRAL call ✓ call won +1.23% · α vs SPY +0.03% · entry $77.75 → $78.71

Next anchor: T+20d in 14d

Last close $83.01 (close Jun 8) · +6.77% from $77.75 entry

Entry anchored
May 26, 03:59 PM ET
via Databento tick

T+1d

+0.09%

call +0.09% · α -0.46%

$77.82

settled 14d ago

T+5d

+1.23%

call +1.23% · α +0.03%

$78.71

settled 8d ago

T+20d

—

call — · α —

—

in 14d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Apogee Therapeutics announced it will release Part B 16-week data from the Phase 2 APEX trial of zumilokibart on May 27, 2026, followed by a conference call. This is a binary catalyst event for the clinical-stage biotech, as zumilokibart is its most advanced program targeting atopic dermatitis, asthma, and eosinophilic esophagitis.

Actionable Insight

The upcoming Phase 2 data readout is a high-impact binary event. Traders should monitor the May 27 results and conference call for efficacy and safety signals. Positive data could drive substantial upside given the large I&I market opportunity; negative data could lead to significant downside.

Key Facts

Part B 16-week data from Phase 2 APEX trial of zumilokibart to be reported on May 27, 2026.
Conference call and webcast scheduled for 8:00 a.m. ET on May 27, 2026.
Zumilokibart is Apogee's most advanced program, targeting atopic dermatitis, asthma, and EoE.
Apogee is a clinical-stage biotechnology company with no approved products or reported revenue.

Financial Impact

No financial data provided; outcome of data readout could significantly impact valuation given early-stage nature.

market_capcash_runway

Risk Factors

Negative or mixed Phase 2 data could severely impact stock price, as zumilokibart is the lead asset.
Clinical-stage biotech with no revenue; cash runway and future financing needs depend on trial outcomes.
Historical performance shows past high-score calls on APGE have had negative average returns, suggesting market skepticism.

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

83% bullish (23 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3301436

19 reports for APGE

T+1T+5T+20T+60

70% Hit rate 7 of 10 directional calls best @ T+20▲ +14.66%Mar 23, 2026

Filters

Reports for APGE — sortable, filterable
	Type				Now
May 27, 2026 13d ago	8-K BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	8-K BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	Press Release BULLISH ★ 7/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 27, 2026 13d ago	Press Release BULLISH ★ 8/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 26, 2026 14d ago	Press Release NEUTRAL ★ 6/10	$77.75 $78.71	▲ +1.23%	▲ +0.03%	$83.01 (+6.77%)
May 16, 2026 25d ago	Insider Cluster NEUTRAL ★ 3/10	$78.75 $82.81	▲ +5.16%	▲ +3.54%	$83.01 (+5.41%)
May 13, 2026 27d ago	144 NEUTRAL ★ 2/10	$83.94 $81.39	▼ −3.04%	▼ −2.90%	$83.01 (−1.11%)
May 11, 2026 29d ago	8-K BULLISH ★ 7/10	$84.60 $78.75	▼ −6.91%	▼ −6.83%	$83.01 (−1.88%)
May 11, 2026 29d ago	Press Release BULLISH ★ 7/10	$84.60 $78.75	▼ −6.91%	▼ −6.83%	$83.01 (−1.88%)
May 1, 2026 5w ago	Insider Cluster NEUTRAL ★ 2/10	$80.75 $83.03	▲ +2.82%	▲ +0.48%	$83.01 (+2.80%)

US Market Status

Market Closed — Opens in 4h 2m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access